Q Therapeutics Inc. (hereinafter Q Therapeutics, Q, we, us, our and similar expressions) is a Salt Lake City, Utah-based biopharmaceutical company that is developing human cell-based therapies that can be sold as “off-the-shelf” pharmaceuticals intended to treat neurodegenerative diseases of the brain and spinal cord, the primary components of the central nervous system or CNS. The technology upon which these potential therapies are based was developed by Q’s co-founder Mahendra Rao, M.D., Ph.D., a leader in glial stem cell biology, during Dr. Rao’s tenure as a Professor at the University of Utah and as Head of the Stem Cell Section in the Laboratory of Neuroscience at the National Institutes of Health (NIH) Institute of Aging. Dr. Rao was one of the first scientists to identify and seek patent coverage on stem cells and their progeny cells found in the CNS.
Company profile
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Grace 2, Inc., Q Holdings, Inc.
SEC CIK
Corporate docs
IRS number
203708500
Latest filings (excl ownership)
REVOKED
Registration or securities revoked
30 Aug 19
8-K
Departure of Directors or Certain Officers
17 Dec 15
8-K
Departure of Directors or Certain Officers
19 Nov 15
10-Q
2015 Q3
Quarterly report
13 Nov 15
424B3
Prospectus supplement
13 Nov 15
8-K
Departure of Directors or Certain Officers
14 Sep 15
10-Q
2015 Q2
Quarterly report
14 Aug 15
424B3
Prospectus supplement
14 Aug 15
8-K
Other Events
4 Jun 15
10-Q
2015 Q1
Quarterly report
11 May 15
Latest ownership filings